ClinicaliQ Trial Snapshot
- A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn’s Disease — Recruiting • Phase III • Gastroenterology • NCT06819878.
- New drug afimkibart tested for safely treating moderate-to-severe Crohn's disease in a phase three trial comparing it against placebo.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This Phase III, multicenter, double-blind, placebo-controlled treat-through study will evaluate the efficacy and safety of induction and maintenance therapy with Afimkibart (also known as RO7790121) in participants with moderately to severely active Crohn's disease (CD). Conditions: Moderately to Severely Active Crohns Disease Interventions: Afimkibart, Placebo Lead Sponsor: Hoffmann-La Roche Planned Enrollment: 600 participants